These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31346133)

  • 1. Pathological Response to Neoadjuvant Chemotherapy and the Molecular Classification of Locally Advanced Breast Cancer in a Latin American Cohort.
    Díaz-Casas SE; Castilla-Tarra JA; Pena-Torres E; Orozco-Ospino M; Mendoza-Diaz S; Nuñez-Lemus M; Garcia-Angulo O; Garcia-Mora M; Guzman-AbiSaab L; Lehmann-Mosquera C; Angel-Aristizabal J; Duarte-Torres C; Vergel-Martinez JC
    Oncologist; 2019 Dec; 24(12):e1360-e1370. PubMed ID: 31346133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between pathological response and molecular subtypes in locally advanced breast cancer patients receiving neoadjuvant chemotherapy.
    Değerli E; Şentürk Öztaş N; Alkan G; Bedir Ş; Derin S; Valıkhanova N; Saraç B; Kacar E; Demirci NS; Demirelli HF; Turna H
    J Chemother; 2023 Feb; 35(1):29-38. PubMed ID: 35220928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Behavior of Triple Negative Breast Cancer in a Cohort of Latin American Women.
    Diaz Casas S; Lancheros García E; Sanchéz Campo A; Sanchez Pedraza R; Roman Vasquez V; Mendoza SD; Angel Aristizabal J; Lehmann Mosquera C; Duarte Torres C; Vergel JC
    Cureus; 2019 Jun; 11(6):e4963. PubMed ID: 31453035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor response to neoadjuvant chemotherapy in molecular breast cancer subtypes in Medellin, Colombia. Retrospective cohort study.
    Restrepo-Mejía M; Guarín-García AM; Bonilla-Sepúlveda ÓA; Rincón-Medina M; Barrera-Arenas LM
    Rev Colomb Obstet Ginecol; 2023 Jun; 74(2):143-152. PubMed ID: 37523685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
    Promberger R; Dubsky P; Mittlböck M; Ott J; Singer C; Seemann R; Exner R; Panhofer P; Steger G; Bergen E; Gnant M; Jakesz R; Bago-Horvath Z; Rudas M; Bartsch R
    Clin Breast Cancer; 2015 Dec; 15(6):505-11. PubMed ID: 26195436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
    Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
    Cortazar P; Zhang L; Untch M; Mehta K; Costantino JP; Wolmark N; Bonnefoi H; Cameron D; Gianni L; Valagussa P; Swain SM; Prowell T; Loibl S; Wickerham DL; Bogaerts J; Baselga J; Perou C; Blumenthal G; Blohmer J; Mamounas EP; Bergh J; Semiglazov V; Justice R; Eidtmann H; Paik S; Piccart M; Sridhara R; Fasching PA; Slaets L; Tang S; Gerber B; Geyer CE; Pazdur R; Ditsch N; Rastogi P; Eiermann W; von Minckwitz G
    Lancet; 2014 Jul; 384(9938):164-72. PubMed ID: 24529560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.
    Das U; Lakshmaiah KC; Govind Babu K; Suresh TM; Lokanatha D; Jacob L; Babu S
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1777-82. PubMed ID: 24894013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
    J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients.
    Luangdilok S; Samarnthai N; Korphaisarn K
    J Breast Cancer; 2014 Dec; 17(4):376-85. PubMed ID: 25548587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
    Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
    Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.
    de Moura Leite L; Cesca MG; Tavares MC; Santana DM; Saldanha EF; Guimarães PT; Sá DDS; Simões MFE; Viana RL; Rocha FG; Loose SK; Silva SF; Pirolli R; Fogassa CAZ; Mattos BRS; Campos FAB; Sanches SM; de Lima VCC; Pondé NF
    Breast Cancer Res Treat; 2021 Nov; 190(1):155-163. PubMed ID: 34409551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy.
    Chou HH; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Yu MC; Lo YF; Dabora MA; Chang HK; Lin YC; Ueng SH; Chen SC
    Biomed J; 2019 Feb; 42(1):66-74. PubMed ID: 30987708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferation rate and breast cancer subtype, but not ALDH1 expression, predict pathological response to neoadjuvant chemotherapy in locally advanced breast cancer.
    Chatterjee D; Bal A; Das A; Singh G
    Virchows Arch; 2015 Sep; 467(3):303-10. PubMed ID: 26063415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial.
    Firouzabadi D; Dehghanian A; Rezvani A; Mahmoudi L; Talei A
    BMC Cancer; 2021 Jan; 21(1):47. PubMed ID: 33430808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma.
    Mohapatra M; Sarma YS
    J Cancer Res Ther; 2020; 16(6):1419-1425. PubMed ID: 33342807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early progression of breast cancer during neoadjuvant chemotherapy may predict poorer prognoses.
    Myller S; Ipatti P; Jääskeläinen A; Haapasaari KM; Jukkola A; Karihtala P
    Acta Oncol; 2020 Sep; 59(9):1036-1042. PubMed ID: 32394761
    [No Abstract]   [Full Text] [Related]  

  • 19. The accuracy of MRI in detecting pathological complete response following neoadjuvant chemotherapy in different breast cancer subtypes.
    Kuzmova M; Cullinane C; Rutherford C; McCartan D; Rothwell J; Evoy D; Geraghty J; Prichard RS
    Surg Oncol; 2023 Dec; 51():102011. PubMed ID: 37931546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer.
    Cuello-López J; Fidalgo-Zapata A; López-Agudelo L; Vásquez-Trespalacios E
    PLoS One; 2018; 13(11):e0207224. PubMed ID: 30427884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.